People suffering from retinal degenerative diseases involving retinal pigment epithelial (RPE) stress may benefit form treatment involving mTOR pathway inhibitors, a new study has suggested.
Research carried out at Stanford University School of Medicine in California, and led by Douglas Vollrath, examined the role played by RPEs, which nourish and support photoreceptors in the retina.
Knowing that RPE cell dysfunction leads to retinal degeneration and loss of visual acuity, the experts also found that mice with RPE stress trigger cell dedifferentiation and this leads to decreased responsiveness of photoreceptor cells to light and their eventual degeneration.
"The authors therefore suggest that mTOR pathway inhibitors might provide a new approach to treating individuals with retinal degenerative diseases involving RPE stress," the specialists said.
In other research, experts led by Dr Mitra Sehi and Dr David Greenfield from the Bascom Palmer Eye Institute at the University of Miami Miller"s School of Medicine have claimed that a new test may eventually help to evaluate how well glaucoma treatments are working.
by Martin Burns